Plain-English translation of NCT06675123 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This small pilot study is testing whether , a new medication, works better when combined with a (a type of cancer medication you may already be taking) in people with mantle cell lymphoma that has come back or stopped responding to prior treatment. Researchers want to see if adding this medication to your current helps shrink the cancer and is safe to take. The study will also look at how this combination affects your cancer cells and immune system.
Mantle cell lymphoma is a serious blood cancer, and some patients' cancers stop responding to standard treatments or come back after an initial response. This medication is being studied to see if it can help patients whose cancer has become resistant to current therapies, potentially offering a new option when standard treatments are no longer working.
You likely qualify if…
You likely don't qualify if…
You will take by mouth twice a day for 28 days in repeating cycles, while continuing your regular medication. Throughout the study, you'll have blood tests, imaging scans (PET/CT), and possibly bone marrow biopsies to see how the treatment is working and monitor for side effects. After treatment ends, you'll have a follow-up visit at 30 days, and then every 3 months if your cancer hasn't progressed.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States